ATR AptarGroup
- 146.810
- +0.890+0.61%
- 146.810
- 0.0000.00%
AptarGroup News
Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR), Dexcom (DXCM) and Aldeyra Therapeutics (ALDX)
Wells Fargo Maintains Overweight on AptarGroup, Raises Price Target to $163
Baird: The AptarGroup (ATR.US) rating was maintained, and the target price was adjusted from better than the market to the better than the market rating, and the target price was adjusted from $150.00 to $170.00.
AptarGroup Analyst Ratings
Baird Maintains Outperform on AptarGroup, Raises Price Target to $170
Analysts Conflicted on These Healthcare Names: AptarGroup (ATR) and Community Health (CYH)
AptarGroup's Strong Q1 Performance and Robust Pharmaceutical Growth Justify Buy Rating
AptarGroup Analyst Ratings
Wells Fargo Maintains Overweight on AptarGroup, Raises Price Target to $160
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX), Sarepta Therapeutics (SRPT) and AptarGroup (ATR)
Analysts Have Conflicting Sentiments on These Healthcare Companies: AptarGroup (ATR), Halozyme (HALO) and Bausch Health Companies (BHC)
AptarGroup's Strong Performance and Growth Prospects Merit a Buy Rating
Baird Upgrades AptarGroup to Outperform, Raises Price Target to $150
AptarGroup Analyst Ratings
Hold Rating on AptarGroup Amid Modest Q3 Profits and Uncertain Q4 Outlook
Positive Financial Outlook Spurs 'Buy' Rating for AptarGroup: A Detailed Analysis of 3Q Performance and 4Q Projections
BofA Securities Adjusts Price Target on AptarGroup to $145 From $150, Maintains Buy Rating
AptarGroup (ATR) Receives a Hold From DBS
DBS Bank Starts AptarGroup at Hold Rating, $132 Price Target
AptarGroup Analyst Ratings
Analysis
Price Target
No Data
